Compare EDBL & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDBL | CMND |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.6M |
| IPO Year | 2021 | 2021 |
| Metric | EDBL | CMND |
|---|---|---|
| Price | $1.19 | $0.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 223.7K | ★ 363.2K |
| Earning Date | 05-15-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,810,000.00 | N/A |
| Revenue This Year | $68.17 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.08 | $0.07 |
| 52 Week High | $8.60 | $4.66 |
| Indicator | EDBL | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 30.05 | 28.45 |
| Support Level | $0.88 | $0.59 |
| Resistance Level | $1.22 | $1.27 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 15.56 | 5.13 |
Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces. Company provides two principal product segments: (i) fresh produce, including cut herbs, hydroponic basil, potted herbs, and wheatgrass; and (ii) shelf-stable and refrigerated consumer packaged goods, including sports nutrition and nutraceuticals.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.